GT Biopharma Inc.

Last updated September 27, 2026

Organization details

Legal name
GT Biopharma Inc.
Former names
Oxis International Inc
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
SAN Francisco
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
GTBP
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0000109657
EIN
94-1620407

Board of directors

Chief executives

Michael Martin Breen · CEO and Director
Dates unknown

Director election results

Annual meeting of June 28, 2023. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

3 of this board's directors also sit on 5 other boards.

Network of GT Biopharma Inc.'s board connections Eton Pharmaceuticals Inc. Eton Pharmaceuticals I... GridAI Technologies Corp. GridAI Technologies Co... ImmunityBio Inc. ImmunityBio Inc. Prairie Operating Co. Prairie Operating Co. Relmada Therapeutics Inc. Relmada Therapeutics I... Bruce Wendel Bruce Wendel Charles J. Casamento Charles J. Casamento Michael Martin Breen Michael Martin Breen GT Biopharma Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Aug 11, 2023 Michael Martin Breen Director, Officer (Executive Chairman/Interim CEO) Grant or award +200,000 $0.29 $58,000
Aug 11, 2023 Ohri Manu Officer (CFO & Secretary) Grant or award +200,000 $0.29 $58,000
Aug 11, 2023 Ohri Manu Officer (CFO & Secretary) Other −200,000 $0.29 $58,000
Aug 11, 2023 Ohri Manu Officer (CFO & Secretary) Other +200,000 $0.29 $58,000
Apr 11, 2023 Michael Martin Breen Director, Officer (Executive Chairman/Interim CEO) Open-market purchase +50,000 $0.50 $25,000
Apr 6, 2023 Ohri Manu Officer (CFO & Secretary) Open-market purchase +50,000 $0.50 $25,000

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.